On the Record · Argenx
Argenx competitors, on the record
The companies whose own annual reports name Argenx as a competitor, each with the sentence it appears in and the filing it came from.
Who Argenx names
Argenx’s annual reports for 2023 to 2025 describe its competition by kind of business and do not name competing companies.
Who names Argenx
Companies whose own annual reports name Argenx as a competitor.
Word for word“GC Biopharma introduced its 10% IVIG product, Alyglo TM , to the U.S. market in 2024 and Argenx obtained FDA approval in 2021 for VYVGART (IV) and in 2024 for VYVGART Hytrulo (subcutaneous), a non-plasma derived product that would treat patients with chronic inflammatory demyelinating polyneuropathy (“CIDP”).” 20-F for 2025
Word for word“Additionally, there are a number of Phase 3 compounds (dazukibart (anti-IFN; Pfizer), anifrolumab (Saphnelo®; anti-IFN; AstraZeneca) and efartigimod (Vyvgart®; anti-FcRn; Argenx) which could launch before the end of the decade.” 20-F for 2025
Read from Argenx’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-03-19. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.